Cancer Research Technology: How close are we to another breakthrough?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cancer Research Technology: How close are we to another breakthrough?
Released on: March 03, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    As the commercialisation arm of Cancer Research UK, Cancer Research Technology (CRT) bridges the gap between academia and industry.
  • Summary
  • Transcript
  • Participants
  • Company
As the commercialisation arm of Cancer Research UK, Cancer Research Technology (CRT) bridges the gap between academia and industry. Keith Blundy, CEO of CRT, gives his unique perspective on recent developments in immuno-oncology and talks about the most promising areas for early-stage discovery.
As the commercialisation arm of Cancer Research UK, Cancer Research Technology (CRT) bridges the gap between academia and industry. Keith Blundy, CEO of CRT, gives his unique perspective on recent developments in immuno-oncology and talks about the most promising areas for early-stage discovery.
Keith joined CRT in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £70m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc. in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics and Cancer Therapeutics Pty and is currently on the board of Cytosystems Ltd and Inivata Ltd. He is also a member of Cancer Research UK’s Scientific Executive Board.
Cancer Research Technology
Cancer Research UK is a cancer research and awareness charity in the United Kingdom, formed on 4 February 2002 by the merger of The Cancer Research Campaign and Imperial Cancer Research Fund.